Guardant Health Inc (GH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guardant Health Inc (GH) has a cash flow conversion efficiency ratio of 0.362x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.62 Million) by net assets ($-181.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GH company net worth for the company's overall valuation and market capitalisation.
Guardant Health Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Guardant Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guardant Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guardant Health Inc ranked by their cash flow conversion efficiency. See Guardant Health Inc cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk
F:PTI
|
0.092x |
|
McCormick & Company Incorporated
NYSE:MKC
|
0.050x |
|
SK Telecom Co Ltd
KO:017670
|
0.080x |
|
China Railway Group Limited
SHG:601390
|
0.013x |
|
Wolters Kluwer N.V.
AS:WKL
|
1.252x |
|
Raytron Technology Co Ltd
SHG:688002
|
0.063x |
|
Wiwynn Corp
TW:6669
|
-0.116x |
|
Industrivarden AB ser. C
ST:INDU-C
|
0.042x |
Annual Cash Flow Conversion Efficiency for Guardant Health Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Guardant Health Inc from 2016 to 2025. View GH live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-99.31 Million | $-184.76 Million | 1.860x | +8.32% |
| 2024-12-31 | $-139.65 Million | $-239.86 Million | 1.718x | +183.87% |
| 2023-12-31 | $158.68 Million | $-324.98 Million | -2.048x | +60.17% |
| 2022-12-31 | $60.18 Million | $-309.46 Million | -5.142x | -1486.86% |
| 2021-12-31 | $645.00 Million | $-209.02 Million | -0.324x | -322.69% |
| 2020-12-31 | $1.36 Billion | $-103.93 Million | -0.077x | -37.93% |
| 2019-12-31 | $847.99 Million | $-47.13 Million | -0.056x | +59.58% |
| 2018-12-31 | $524.95 Million | $-72.19 Million | -0.138x | +41.25% |
| 2017-12-31 | $308.61 Million | $-72.23 Million | -0.234x | +49.18% |
| 2016-12-31 | $79.70 Million | $-36.71 Million | -0.461x | -- |
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more